Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pionex Management Group Pharm
South Koreapionex.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Pionex Management Group Pharm has developed at least one approved drug, PG‑201, targeting IL‑1β and TNF‑α for osteoarthritis. The company also has several pending or investigational programs in arthritis and knee osteoarthritis. Clinical trial activity includes at least six trials with a focus on herbal medicines and anti-inflammatory mechanisms.
- Therapeutic areas
- Rheumatology
- Modalities
- Herbal medicineSmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Pionex Management Group Pharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pionex Management Group Pharm.